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Background: Tuberculosis (TB) and HIV are among the risk factors for deep vein thrombosis (DVT). There are
several challenges in the management of DVT patients with TB-HIV co-infection including drug-drug interactions
and non-adherence due to pill burden.
Methods: HIV infected patients starting treatment for TB were identified and followed up two weekly. Cases of DVT
were diagnosed with Doppler ultrasound and patients were initiated on oral anticoagulation with warfarin and
followed up with repeated INR measurements and warfarin dose adjustment.
Results: We describe 7 cases of TB and HIV-infected patients in Uganda diagnosed with DVT and started on
anticoagulation therapy. Their median age was 30 (IQR: 27–39) years and 86 % were male. All patients had
co-medication with cotrimoxazole, tenofovir, lamivudine and efavirenz and some were on fluconazole. The
therapeutic range of the International Normalization Ratio (INR) was difficult to attain and unpredictable with
some patients being under-anticoagulated and others over-anticoagulated. The mean Time in Therapeutic Range
(TTR) for patients who had all scheduled INR measurements in the first 12 weeks was 33.3 %. Only one patient
among those with all the scheduled INR measurements had achieved a therapeutic INR by 2 weeks. Four out of
seven (57 %) of the patients had at least one INR above the therapeutic range which required treatment
interruption. None of the patients had major bleeding.
Conclusion: We recommend more frequent monitoring and timely dose adjustment of the INR, as well as
studies on alternative strategies for the treatment of DVT in TB-HIV co-infected patients.
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The risk of deep vein thrombosis (DVT) is one and a half
times higher among patients with tuberculosis (TB) com-
pared to those without TB [1] due to a hypercoagulable
state which occurs among patients with TB resulting from
endothelial dysfunction due to the mycobacteria, in-
creased fibrinogen, fibrin, tissue plasminogen activator,
decreased anti-thrombin III [2, 3] and use of rifampicin
especially in the first two weeks following TB treatment* Correspondence: csekaggya@idi.co.ug
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(http://creativecommons.org/publicdomain/zeinitiation [4]. Furthermore HIV infection, which is the
highest risk factor for TB, is also considered a pro-
thrombotic condition occurring most commonly in those
with a low CD4 cell count [5, 6]. The mechanism leading
to DVT in HIV is thought to be multifactorial including
Protein C, S and antithrombin deficiency and increased
antiphospholipid and antilupus antibodies [7, 8].
Several challenges due to drug-drug interactions occur
during the management of DVT in patients co-infected
with HIV and TB. Warfarin is metabolized by CYP450
pathway. Therefore drugs which induce this pathway (ri-
fampicin and nevirapine) or inhibit them (isoniazid and
efavirenz) could lead to under-anticoagulation or over-le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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the ability to attain the therapeutic target required for
adequate anticoagulation [9]. Table 1 demonstrates drug
interactions that may occur in patients with HIV and
TB.
Several case series have discussed the occurrence of
thrombosis in patients with TB [10, 11] and in those
with HIV [12, 13], however, in this case series we dem-
onstrate the challenges encountered when trying to
achieve an International Normalized Ratio (INR) within
the therapeutic window with warfarin in this population
of TB-HIV co-infected patients.
Methods
The cases described are from patients enrolled in the
“Study of Outcomes in TB-HIV co-infected patients”
(SOUTH), a study conducted at the integrated HIV and TB
clinic at the Infectious Diseases Institute in Kampala [14].
The SOUTH study aims to investigate the relationship be-
tween anti-TB drug concentrations and treatment out-
comes in HIV infected patients treated for pulmonary TB
(PTB). Patients are reviewed by a clinician every two weeks
during the first two months of their treatment and monthly
subsequently. Patients with clinical symptoms of TB are in-
vestigated using chest x-ray, sputum smear microscopy,
sputum culture for Mycobacterium tuberculosis and Xpert
MTB/RIF. Patients were followed up starting from the day
TB treatment was initiated. TB treatment included a fixed
dose regimen consisting of two months of rifampicin, iso-
niazid, pyrazinamide and ethambutol followed by four
months of rifampicin and isoniazid. CD4 counts were mea-
sured within two weeks prior to or after TB diagnosis. Pa-
tients were initiated on antiretroviral therapy (ART) after
the second week of anti-TB treatment according to WHO
guidelines [15, 16] and included tenofovir, lamivudine and
efavirenz. Patients remained on this ART regimen through-
out the follow-up period. All patients were on cotrimoxa-
zole before the start of the study and also remained on itTable 1 Drug interactions in patients with HIV and TB
DRUG EFFECT ON CYTOCHROME P450
Induce Cytochrome P450
(Decrease effect of warfarin)
Inhibit Cytochrome P450










aEfavirenz may induce or inhibit cytochrome P450 through its action on CYP3A4
and CYP2C9 respectivelythroughout follow-up. Cases of DVT were identified by
clinical history and physical examination between May
2013 and June 2015; all patients who reported or were ob-
served to have limb swelling were referred for Doppler
ultrasound scan to confirm the clinical diagnosis. Patients
diagnosed with DVT were initiated on warfarin tablets
(Bristol®) at an initial dose of 2.5 - 5 mg once daily, as well
as low molecular heparin (LMWH), Enoxaparin (Clexane®)
1 mg/kg for five days and subsequently continued on war-
farin alone. The INR was monitored weekly and dose ad-
justment was made at the discretion of the clinician
depending on the INR results. Adherence to warfarin was
assessed through self-report and the number of days that
warfarin doses were missed were recorded in the patient’s
file. Patients who missed a visit were called on the same
day and rescheduled for the closest opportunity within the
same week. Time in therapeutic range (TTR) was calcu-
lated as the number of therapeutic INR values during the
first 12 weeks of anticoagulation as a percentage of all the
INR values measured during this same period.
Informed consent was obtained from all patients prior
to involvement in the study.
The study was reviewed and approved by the Joint
Clinical Research Centre Research and Ethics Commit-
tee and the Uganda National Council for Science and
Technology (HS 1303).
Results
During this review period, 7/268 (2.6 %) patients with
confirmed PTB presented with pain and swelling of the
lower limb and were diagnosed with DVT through Dop-
pler ultrasound scan. All patients were HIV positive. In-
dividual patients’ characteristics are displayed in Table 2.
Six (86 %) were male with a median age of 30 (interquar-
tile range (IQR): 27–39) years and a median CD4 count
at the time of TB diagnosis of 72cells/μl (19–78). All pa-
tients were not on ART at the time of anti-TB treatment
initiation and started on tenofovir, lamivudine and efa-
virenz after two weeks of TB treatment. The median
time from initiation of anti-TB treatment to DVT diag-
nosis was 2 (IQR: 2–4) weeks. From their clinical his-
tory, none of the patients was bedridden at the time of
DVT diagnosis.
Three patients were on 600-800 mg of fluconazole be-
fore the diagnosis of DVT was made (patients 1, 5 and 7)
due to cryptococcal antigenemia. Figure 1 below shows
the trend of INR values for each patient while Table 3
shows the corresponding warfarin doses.
Patient 1 was started on the standard ART mentioned
ten days after the diagnosis of DVT was made. He had
only one therapeutic INR during the first 12 weeks of
anticoagulation with a TTR of 8.3 %. Three of his INR
measurements were supratherapeutic with no major
bleeding while taking 7.5 mg and 5 mg respectively which
Table 2 Patient baseline characteristics
Patient number Age (years) Gender Baseline CD4 (cells/μL) Week of TB treatment
when DVT diagnosed
Symptoms of bleeding Co-medicationa
1 30 M 6 1.5 No CTX, Fluconazole
2 26 M 73 4 No CTX
3 40 F 40 2 Epistaxis CTX
4 39 M 72 10 No CTX
5 27 M 78 2 Epistaxis CTX, fluconazole
6 31 M 19 4 No CTX
7 28 M 180 2 No CTX, fluconazole
M male, F female, CTX cotrimoxazole
aAll patients were on tenofovir, lamivudine and efavirenz
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maximum dose during this period was 10 mg. He was on
fluconazole throughout the follow-up period.
Patient 2, who had started ART two weeks prior to the
diagnosis of DVT had a supratherapeutic INR after
3 weeks of anticoagulation while on 10 mg of warfarin
with no major bleeding episode. From 8 weeks onwards,
his INR was maintained within the therapeutic range on
10 mg. His TTR was 41.7 %.
Patient 3 had a therapeutic INR at the earliest time
point compared to the other patients (1 week) and had
the best INR control. She developed DVT two weeks
into her TB treatment and ART and warfarin were
started at the same time. She had a supratherapeutic
INR while on 10 mg of warfarin with epistaxis. She later
had a therapeutic INR initially on 5 mg and later 7.5 mg
of warfarin. She had the highest TTR of 58.3 %.
Patient 4 had a history of alcohol abuse and had five
intermittent INR measurements (1.53 at week one, 2.10 at
week two, 1.29 at week six, 1.04 at week ten and 1.29 at
week twelve) He missed visits at weeks 3, 4, 5, 7, 8, 9, 11
despite phone call reminders to come to the clinic. He ad-
mitted to poor adherence whenever he run out of pills.Fig. 1 INR trends during the first 12 weeks of anticoagulationPatient 5 started on ART on the day DVT was diag-
nosed, and was also on fluconazole. He had suprathera-
peutic INR on a dose of 5 mg of warfarin. This same
dose subsequently kept him within the therapeutic range
for most of the time after week 6 even while he was still
on fluconazole and his TTR was 41.7 %.
Patient 6 was diagnosed with DVT a week after starting
ART. He had dose escalation up to 12.5 mg, the highest
dose used among these patients, and only attained a thera-
peutic INR at two time points. He attained the lowest
TTR of 16.7 %.
Patient 7 had only 2 INR measurements after 1 and
3 weeks (1.15 and 2.21 respectively) and there after re-
quested to be transferred to another center.
The mean TTR for patients who had all scheduled
INR measurements in the first 12 weeks was 33.3 %.
Only one patient (patient 3) among those with all the
scheduled INR measurements had achieved a thera-
peutic INR by 2 weeks.
Four out of seven (57 %) of the patients (cases 1, 2, 3
and 5) had at least one INR above the therapeutic range
which required treatment interruption. Two patients de-
veloped epistaxis (patient 5 and 3); however none of them
experienced severe bleeding. Patient 1 had supratherapeu-
tic INR values at weeks 4, 8 and 11 and the INR only
reached the therapeutic range once during the first
12 weeks of treatment despite several dose adjustments
each week as shown in the graph below.
Of the remaining two patients, one (patient 7) missed
several clinic visits and subsequently asked to be trans-
ferred to another health care center and patient 4 fre-
quently missed clinic visits and achieved therapeutic
ranges only at time point (week 4). All patients reported
100 % adherence except patients 4 and 7 who missed over
60 % of their warfarin doses during the follow-up period.
Discussion
Achieving a target INR was challenging in our TB-HIV
co-infected population, and we supposed that drug-drug
interactions and unreported non-adherence could have
Table 3 Warfarin doses adjustments per week
Patient number Dose of warfarin (mg)
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12
Patient 1 5 7.5 7.5 7.5 0 5 7.5 10 0 5 5 0
Patient 2 5 7.5 10 0 5 7.5 7.5 10 10 10 10 10
Patient 3 5 10 10 0 2.5 5 5 5 7.5 7.5 7.5 7.5
Patient 5 2.5 5 0 0 5 5 5 5 5 5 5 5
Patient 6 2.5 5 5 7.5 7.5 10 10 12.5 12.5 12.5 12.5 12.5
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resulted in supratherapeutic or subtherapeutic INR
values. On some occasions, the same dose of warfarin
that kept a patient within the therapeutic range would
also lead to a subtherapeutic or supratherapeutic INR
later as in the case of patients 1 and 2 which could be
due to drug interactions or non-adherence that was not
reported.
Warfarin prescriptions increase the pill burden in TB-
HIV co-infected patients who are already taking up to 9
tablets per day. Pill burden has been shown to enhance
non-adherence [17] and therefore contribute to difficulty
in attaining a target INR.
Drug interactions with fluconazole, which increases
the effect of warfarin through inhibition of CYP2C9 and
CYP3A4, may explain the low daily warfarin require-
ment for patients 1 and 5 compared to the other pa-
tients. Patient 1 also had several supratherapeutic INR
values due to the increased effect of warfarin. Drug-drug
interactions between warfarin and fluconazole has also
been reported by others [18].
All patients were on rifampicn, isoniazid and efavirenz,
making it difficult to ascertain which of these drugs con-
tributed to the subtherapeutic or supratherapeutic INR
values; however, the challenge of drug-drug interactions
is evident. Lee et al. reported that a 233 % increase in
warfarin dosage over 4 months was insufficient to attain
an INR within the therapeutic range in a patient on ri-
fampicin [19].
Where there are drug interactions, a switch to a more
suitable option is necessary, however we recognize that
there are not many alternative therapies for treatment of
DVT; therefore this may not be practical. Newer drugs
like factor Xa inhibitors also pose a challenge due to
drug-drug interactions in patients on TB treatment and
ART as is the case of warfarin. LMWH which is the rec-
ommended anticoagulation therapy in patients with can-
cer, may be suitable for this patient population, an area
that also needs to be explored further considering the
similar mechanisms of thrombosis involving an increase
in inflammatory markers.
Most INR values measured in these patients were out-
side the therapeutic range and the mean time in the thera-
peutic range for all the patients with regular follow-upwas only 33.3 %. Although we did not have a direct meas-
ure of clinical improvement, TTR has been shown to cor-
relate with DVT treatment outcome and is used in the
assessment of the management of DVT [20]. There are
however many methods of measurement of TTR which
may limit its utility in day to day practice. Time in thera-
peutic range has been reported to be higher in other stud-
ies (56 %–75 %) [21] in comparison to our patients.
Our time in therapeutic range may have implications
on the duration of treatment that is adequate to achieve
actual resolution of symptoms and resorption of the
thrombus. Further studies need to evaluate if prolonging
treatment in patients with low TTR values affects DVT
treatment outcomes.
Conclusion
The course of INR in this population was unpredictable
in any individual patient. This could be due to a number
of reasons including non-adherence and changing dose
requirements due to drug interactions.
More frequent monitoring of INR with timely dose ad-
justments is required in TB-HIV patients. Studies on al-
ternative medication for example long term LMWH in
TB-HIV infected patients should be considered.
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